Abstract
Using the yeast two-hybrid system we have identified novel potential Cdk4 interacting proteins. Here we described the interaction of Cdk4 with a human homologue of the yeast Drosophila CDC37 gene products. Cdc37 protein specifically interacts with Cdk4 and Cdk6, but not with Cdc2, Cdk2, Cdk3, Cdk5 and any of a number of cyclins tested. Cdc37 is not an inhibitor nor an activator of the Cdk4/cyclin D1 kinase, while it appears to facilitate complex assembly between Cdk4 and cyclin D1 in vitro. Cdc37 competes with p16 for binding to Cdk4, suggesting that p16 might exert part of its inhibitory function by affecting the formation of Cdk4/cyclin D1 complexes via Cdc37.
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Lamphere, L., Fiore, F., Xu, X. et al. Interaction between Cdc37 and Cdk4 in human cells. Oncogene 14, 1999–2004 (1997). https://doi.org/10.1038/sj.onc.1201036
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201036
Keywords
- Cdk
- cyclin
- cdc37
- hsp90
Further reading
-
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
British Journal of Cancer (2021)
-
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
Drugs (2018)
-
Treating cancer with selective CDK4/6 inhibitors
Nature Reviews Clinical Oncology (2016)
-
Cdc37 engages in stable, S14A mutation-reinforced association with the most atypical member of the yeast kinome, Cdk-activating kinase (Cak1)
Cell Stress and Chaperones (2014)
-
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors
Oncogene (2009)